title: Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)".
authors.affiliation: Tufts University School of Medicine Boston, MA.
authors.forename: Ioana R
authors.initials: IR
authors.lastname: Preston
authors.affiliation: Tufts University School of Medicine Boston, MA.
authors.forename: Kari E
authors.initials: KE
authors.lastname: Roberts
authors.affiliation: ICON Clinical Research San Francisco, CA.
authors.forename: Dave P
authors.initials: DP
authors.lastname: Miller
authors.affiliation: ICON Clinical Research San Francisco, CA.
authors.forename: Ginny P
authors.initials: GP
authors.lastname: Sen
authors.affiliation: Actelion Pharmaceuticals US Inc South San Francisco, CA.
authors.forename: Mona
authors.initials: M
authors.lastname: Selej
authors.affiliation: Actelion Pharmaceuticals US Inc South San Francisco, CA.
authors.forename: Wade W
authors.initials: WW
authors.lastname: Benton
authors.affiliation: Tufts University School of Medicine Boston, MA.
authors.forename: Nicholas S
authors.initials: NS
authors.lastname: Hill
authors.affiliation: Boston University School of Medicine Boston, MA.
authors.forename: Harrison W
authors.initials: HW
authors.lastname: Farber
mesh_terms: D019468:Disease Management; D065627:Familial Primary Pulmonary Hypertension; D006801:Humans; D006976:Hypertension, Pulmonary; D012042:Registries; D015996:Survival Rate; D014859:Warfarin
chemical_list: D014859:Warfarin